Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Managing Amyloidosis in 2024: Diagnosis and Treatment

Indy Hematology Review

M. Gertz

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Management of AL Amyloidosis

GRACE

S. Rajeeve

Experts Discuss the Management of Monoclonal Gammopathy of Renal Sig…

MyCancerHaven

R. Vij, N. Leung

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

POEMS Syndrome Management

MyCancerHaven

R. Vij, D. Dingli

Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…

Scripps Health

M. Gertz

Updates on AL Amyloidosis Treatment: What’s New in 2024

Dana-Farber Cancer Institute

G. Bianchi

Key Myeloma & MGUS Updates From ASH

Memorial Sloan Kettering Cancer Center

S. Mailankody

Smoldering Myeloma: If and When to Treat

Victor Jimenez Zepeda

Treating Amyloidosis in 2024

MyCancerHaven

R. Vij, J. Zonder

Diagnosing AL Amyloidosis

GRACE

S. Rajeeve

Management of Smoldering Myeloma

XV Eurasian Hematology-Oncology Congress - EHOC 2024

C. Cerchione

ASH 2024 Insights: Cilta-Cel CAR-T in High-Risk SMM - Results From C…

2024 ASH Annual Meeting Insights Hub

O. Nadeem

"You Have AL-Amyloidosis": Counseling Newly Diagnosed Patients

Morie Gertz

Updates in the Management of SMM/MGUS and the Prevention of Progress…

Dana-Farber Cancer Institute

Y. Liu

Experts Discuss Novel Antibodies for the Management of Amyloidosis

MyCancerHaven

R. Vij, S. Lentzsch

Why We Should Not Treat SMM

PleXus Communications

B. Derman

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy & Safe…

Insights from 2023 ASH Annual Meeting

O. Landgren